BR112023017754A2 - Derivados de indol como agentes serotonérgicos úteis para o tratamento de distúrbios relacionados com o mesmo - Google Patents
Derivados de indol como agentes serotonérgicos úteis para o tratamento de distúrbios relacionados com o mesmoInfo
- Publication number
- BR112023017754A2 BR112023017754A2 BR112023017754A BR112023017754A BR112023017754A2 BR 112023017754 A2 BR112023017754 A2 BR 112023017754A2 BR 112023017754 A BR112023017754 A BR 112023017754A BR 112023017754 A BR112023017754 A BR 112023017754A BR 112023017754 A2 BR112023017754 A2 BR 112023017754A2
- Authority
- BR
- Brazil
- Prior art keywords
- indol
- treatment
- disorders
- related disorders
- useful
- Prior art date
Links
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical class C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 title abstract 3
- 239000003762 serotonin receptor affecting agent Substances 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 6
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 abstract 2
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 abstract 2
- 230000003213 activating effect Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- TXQAZWIBPGKHOX-UHFFFAOYSA-N 1H-indol-3-amine Chemical class C1=CC=C2C(N)=CNC2=C1 TXQAZWIBPGKHOX-UHFFFAOYSA-N 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 229940054051 antipsychotic indole derivative Drugs 0.000 abstract 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 abstract 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 abstract 1
- 150000002475 indoles Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
derivados de indol como agentes serotonérgicos úteis para o tratamento de distúrbios relacionados com o mesmo. o presente pedido refere-se aos derivados de 3-amino-indol da fórmula geral (i-a), aos processos para a sua preparação, às composições compreendendo os mesmos e ao seu uso na ativação de um receptor de serotonina em uma célula, assim como para tratar doenças, transtornos ou condições pela ativação de um receptor de serotonina em uma célula. as doenças, transtornos ou condições incluem, por exemplo, psicose, doenças mentais e transtornos do cns.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163155634P | 2021-03-02 | 2021-03-02 | |
| PCT/CA2022/050295 WO2022183287A1 (en) | 2021-03-02 | 2022-03-02 | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023017754A2 true BR112023017754A2 (pt) | 2023-11-21 |
Family
ID=83153685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023017754A BR112023017754A2 (pt) | 2021-03-02 | 2022-03-02 | Derivados de indol como agentes serotonérgicos úteis para o tratamento de distúrbios relacionados com o mesmo |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20240166630A1 (pt) |
| EP (2) | EP4301747A1 (pt) |
| JP (2) | JP2024508922A (pt) |
| KR (2) | KR20230154220A (pt) |
| CN (2) | CN117500788A (pt) |
| AU (2) | AU2022229037A1 (pt) |
| BR (1) | BR112023017754A2 (pt) |
| CA (2) | CA3210270A1 (pt) |
| IL (2) | IL305622A (pt) |
| WO (2) | WO2022183288A1 (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021276656A1 (en) | 2020-05-19 | 2022-11-24 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| WO2024046837A1 (en) * | 2022-08-31 | 2024-03-07 | Cybin Irl Limited | Tryptamine compounds, compositions, and methods of use |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1379239B1 (en) * | 2001-03-29 | 2007-09-12 | Eli Lilly And Company | N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor |
| TWI318621B (en) * | 2006-08-03 | 2009-12-21 | Nat Bureau Of Controlled Drugs Dept Of Health | A series of deuterium labelled compounds as drug testing standards and their preparations |
| US20090062367A1 (en) * | 2007-08-29 | 2009-03-05 | Protia, Llc | Deuterium-enriched eletriptan |
| DK2753605T3 (da) * | 2011-09-09 | 2019-06-17 | Lantheus Medical Imaging Inc | Sammensætninger, fremgangsmåder, og systemer til syntesen og anvendelsen af billeddannelsesmidler |
| US20190358238A1 (en) * | 2016-11-16 | 2019-11-28 | University Of South Florida | ALLOSTERIC ANTAGONISTS OF GPRC6a AND THEIR USE IN MITIGATING PROTEINOPATHIES |
| JP2022525036A (ja) * | 2019-03-07 | 2022-05-11 | アーバーメンティス・エルエルシー | 非サイケデリック／精神異常発現性の投与量及び製剤で投与される神経可塑性作用を有する物質を含む組成物並びに使用方法 |
| GB201907871D0 (en) * | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| AU2021215709A1 (en) * | 2020-02-04 | 2022-09-01 | Mindset Pharma Inc. | 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of CNS disorders |
| JP2023513680A (ja) * | 2020-02-04 | 2023-04-03 | マインドセット ファーマ インコーポレイテッド | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体 |
| WO2021218896A1 (zh) * | 2020-04-26 | 2021-11-04 | 江苏恒瑞医药股份有限公司 | 海鞘素类衍生物及其制备方法与医药用途 |
| WO2021234608A1 (en) * | 2020-05-19 | 2021-11-25 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
-
2022
- 2022-03-02 KR KR1020237033368A patent/KR20230154220A/ko unknown
- 2022-03-02 AU AU2022229037A patent/AU2022229037A1/en active Pending
- 2022-03-02 CA CA3210270A patent/CA3210270A1/en active Pending
- 2022-03-02 IL IL305622A patent/IL305622A/en unknown
- 2022-03-02 BR BR112023017754A patent/BR112023017754A2/pt unknown
- 2022-03-02 CN CN202280032370.6A patent/CN117500788A/zh active Pending
- 2022-03-02 US US18/279,293 patent/US20240166630A1/en active Pending
- 2022-03-02 US US18/279,290 patent/US20240166599A1/en active Pending
- 2022-03-02 EP EP22762290.9A patent/EP4301747A1/en active Pending
- 2022-03-02 WO PCT/CA2022/050296 patent/WO2022183288A1/en active Application Filing
- 2022-03-02 KR KR1020237033351A patent/KR20230154219A/ko unknown
- 2022-03-02 AU AU2022229695A patent/AU2022229695A1/en active Pending
- 2022-03-02 IL IL305481A patent/IL305481A/en unknown
- 2022-03-02 CN CN202280032373.XA patent/CN117242065A/zh active Pending
- 2022-03-02 CA CA3210275A patent/CA3210275A1/en active Pending
- 2022-03-02 JP JP2023553664A patent/JP2024508922A/ja active Pending
- 2022-03-02 EP EP22762289.1A patent/EP4301730A1/en active Pending
- 2022-03-02 JP JP2023553660A patent/JP2024508545A/ja active Pending
- 2022-03-02 WO PCT/CA2022/050295 patent/WO2022183287A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| US20240166630A1 (en) | 2024-05-23 |
| AU2022229695A1 (en) | 2023-09-28 |
| JP2024508922A (ja) | 2024-02-28 |
| CA3210275A1 (en) | 2022-09-09 |
| IL305622A (en) | 2023-11-01 |
| CN117242065A (zh) | 2023-12-15 |
| CA3210270A1 (en) | 2022-09-09 |
| WO2022183288A1 (en) | 2022-09-09 |
| KR20230154220A (ko) | 2023-11-07 |
| AU2022229037A1 (en) | 2023-09-28 |
| CN117500788A (zh) | 2024-02-02 |
| EP4301730A1 (en) | 2024-01-10 |
| US20240166599A1 (en) | 2024-05-23 |
| JP2024508545A (ja) | 2024-02-27 |
| IL305481A (en) | 2023-10-01 |
| WO2022183287A1 (en) | 2022-09-09 |
| EP4301747A1 (en) | 2024-01-10 |
| KR20230154219A (ko) | 2023-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022015377A2 (pt) | Derivados de psilocina como agentes psicodélicos serotonérgicos para o tratamento de distúrbios do snc | |
| BR112022015379A2 (pt) | Derivados de 3-pirrolidino-indol como agentes psicodélicos serotonérgicos para o tratamento de distúrbios do snc | |
| BR112023017754A2 (pt) | Derivados de indol como agentes serotonérgicos úteis para o tratamento de distúrbios relacionados com o mesmo | |
| BR112014011333A2 (pt) | derivados de pregenen-11ss-17-21-triol-3,20-diona para o tratamento de condições oculares | |
| AR054786A1 (es) | (6-fluor-benzol(1,3) dioxolil)-morfolin-4-il-metanomas, moduladoras del receptor cb1 | |
| BR112012010866A2 (pt) | "nova construção de vetor viral para síntese específica otimizada contínua de dopa por neurônios in vivo". | |
| BRPI1009381B8 (pt) | compostos, composição farmacêutica e uso de compostos e de composição farmacêutica | |
| ECSP066856A (es) | Compuestos novedosos como moduladores del receptor opioide | |
| BR0315234A (pt) | Derivados de indol como agonistas beta-2 | |
| BR112018015419A2 (pt) | degradantes seletivos de receptor de estrogênio e os usos dos mesmos | |
| BRPI1007018B8 (pt) | composto ligante de receptores de adenosina, composição farmacêutica, e, uso de um composto. | |
| BRPI0408369A (pt) | derivados de indol úteis para o tratamento de doenças | |
| BR112013018515A2 (pt) | derivados de pirrol tricíclico, processo para preparação e seu uso como inibidores da quinase | |
| CL2011002837A1 (es) | Compuestos derivados de 1,2,4-triazolo[4,3-a]piridina, moduladores alostericos positivos de receptores mglur2; composicion farmaceutica; proceso para prepararla; y su uso en el tratamiento o la prevencion de un trastorno del sistema nervioso central tal como la ansiedad, esquizofrenia y migraña, entre otros. | |
| BRPI0508724A (pt) | derivados do fenilaminoetanol como agonistas do receptor beta2 | |
| BR112013000254A2 (pt) | derivados heterocíclicos 1-fenil-substituídos e seu uso como moduladores do receptor de prostaglandina d2 | |
| BRPI0713443A2 (pt) | Derivados de piperazinila úteis no tratamento de doenças medianas por receptor gpr38, uso e composição farmacêutica contendo tais compostos e processos para preparação dos mesmos | |
| CL2011000137A1 (es) | Uso de compuestos derivados de 4,5-dihidro-oxazol-2-ilamina para tratar trastornos de ansiedad, trastornos bipolar, esquizofrenia, enfermedades neurológicas, epilepsias, migraña, trastornos metabólicos, trastornos cardiovasculares, entre otros; compuestos derivados de 4,5-dihidroxazol-2-ilamino; proceso de síntesis | |
| BR112017012588B8 (pt) | Compostos heteroaril-heteroarila bicíclicos de ácido benzoico, seus usos, composições farmacêuticas, métodos de preparação destas e métodos para provocar ou promover o desenvolvimento de neuritos, o crescimento de neuritos e/ou a regeneração de neuritos e para ativar o receptor beta do ácido retinoico | |
| BRPI0411661A (pt) | derivados de n-fenil-piperazina e métodos de profilaxia ou tratamento de doenças associadas com o receptor 5ht 2c | |
| BR112021024117A2 (pt) | Pirazolo-pirazinas substituídas e seu uso como moduladores do receptor de glun2b | |
| BR112012024114A2 (pt) | derivados de 3- (heteroarilamino)-1,2,3,4- tetrahidro-9h-carbazol e o seu uso como moduladores do receptor de prostaglandina d2. | |
| NO20082679L (no) | Sammensetning og fremgangsmate for a behandle CNS lidelser | |
| BR112021024856A2 (pt) | Amidas pirazolo-piridina substituídas e seu uso como moduladores do receptor de glun2b | |
| Kothandan et al. | Evaluation of in vitro antiviral activity of Vitex Negundo L., Hyptis suaveolens (L) poit., Decalepis hamiltonii Wight & Arn., to Chikungunya virus |